SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
58:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
for  patients with platinum-sensitive ovar-:@0.120589:0.094740:0.475137:0.094740:0.475137:0.080735:0.120589:0.080735:0.005371:0.011203:0.005148:0.004738:0.005910:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.010656:0.014214:0.003421:0.005798:0.010434:0.010656:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.010399:0.016044:0.005679:0.006636:0.011118:0.010434:0.006636:0.003421:0.005798:0.003421:0.009476:0.011118:0.010656:0.011203:0.009476:0.011682:0.005148:0.005679
ian cancer in late relapse. :@0.120589:0.108874:0.358152:0.108874:0.358152:0.094869:0.120589:0.094869:0.003421:0.011682:0.010434:0.008860:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.008860:0.003421:0.010434:0.008860:0.003421:0.011682:0.005798:0.011118:0.008860:0.005077:0.011118:0.003421:0.011682:0.011665:0.006640:0.011118:0.004738:0.004738
J Clin Oncol:@0.362274:0.108874:0.470408:0.108874:0.470408:0.094869:0.362274:0.094869:0.008244:0.008860:0.013906:0.003421:0.003421:0.010434:0.008860:0.014864:0.010434:0.011067:0.011203:0.003421
. :@0.470408:0.108874:0.479883:0.108874:0.479883:0.094869:0.470408:0.094869:0.004738:0.004738
2010;28:3323-3329.:@0.120589:0.123009:0.273143:0.123009:0.273143:0.109004:0.120589:0.109004:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
15.   Pujade-Lauraine  E,:@0.084242:0.137144:0.278926:0.137144:0.278926:0.123138:0.084242:0.123138:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.010399:0.003472:0.011682:0.011716:0.011118:0.005679:0.007902:0.011682:0.010399:0.005148:0.011682:0.003421:0.010434:0.011118:0.004738:0.003713:0.009168:0.004738
  et  al.:@0.278926:0.137144:0.332593:0.137144:0.332593:0.123138:0.278926:0.123138:0.004738:0.003718:0.011118:0.005798:0.004738:0.003715:0.011682:0.003421:0.004738
  AURELIA:  a  ran-:@0.332593:0.137144:0.475151:0.137144:0.475151:0.123138:0.332593:0.123138:0.004738:0.003718:0.012657:0.011203:0.010382:0.009168:0.007902:0.003866:0.012657:0.004738:0.004738:0.003707:0.011682:0.004738:0.003720:0.005148:0.011682:0.010434:0.005679
domised phase III trial evaluating bevaci-:@0.120589:0.151278:0.475128:0.151278:0.475128:0.137273:0.120589:0.137273:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007406:0.011665:0.010434:0.011682:0.006636:0.011118:0.007406:0.003866:0.003866:0.003866:0.007406:0.005798:0.005148:0.003421:0.011682:0.003421:0.007406:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.003421:0.010434:0.011511:0.007406:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.005679
zumab  (BEV) plus chemotherapy  (CT)  for :@0.120589:0.165413:0.479895:0.165413:0.479895:0.151408:0.120589:0.151408:0.007269:0.010399:0.016044:0.011682:0.011665:0.004738:0.003530:0.006312:0.009818:0.009168:0.012007:0.006312:0.008279:0.011665:0.003421:0.010399:0.006636:0.008279:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.003520:0.006312:0.013906:0.007286:0.006312:0.004738:0.003532:0.005371:0.011203:0.005148:0.004738
platinum (PT)-resistant recurrent ovarian :@0.120589:0.179548:0.479885:0.179548:0.479885:0.165542:0.120589:0.165542:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.010399:0.016044:0.013701:0.006312:0.010126:0.007286:0.006312:0.005679:0.005077:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.013701:0.005078:0.011118:0.011067:0.010399:0.005148:0.005070:0.011118:0.010434:0.005798:0.013701:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738
cancer (OC). :@0.120589:0.193682:0.238541:0.193682:0.238541:0.179677:0.120589:0.179677:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006568:0.006312:0.014864:0.013906:0.006312:0.004738:0.004738
J Clin Oncol.:@0.240371:0.193682:0.348659:0.193682:0.348659:0.179677:0.240371:0.179677:0.008244:0.006568:0.013906:0.003421:0.003421:0.010434:0.006568:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2012:30(Suppl):@0.348659:0.193682:0.475123:0.193682:0.475123:0.179677:0.348659:0.179677:0.006568:0.009476:0.009476:0.009476:0.009476:0.004750:0.009476:0.009476:0.006312:0.008518:0.010399:0.011665:0.011665:0.003421:0.006312
(AbstLBA5002).:@0.120589:0.207817:0.242988:0.207817:0.242988:0.193812:0.120589:0.193812:0.006312:0.012657:0.011665:0.006636:0.005798:0.007902:0.009818:0.012657:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
16.   Moore DH, Tian C, Monk BJ, :@0.084242:0.221951:0.355603:0.221951:0.355603:0.207946:0.084242:0.207946:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015719:0.011203:0.011203:0.005070:0.011118:0.005217:0.012726:0.011682:0.004738:0.005217:0.007810:0.003421:0.011682:0.010434:0.005217:0.013906:0.004738:0.005217:0.015719:0.011203:0.010434:0.008586:0.005217:0.009818:0.008244:0.004738:0.004738
et al:@0.356082:0.221951:0.393318:0.221951:0.393318:0.207946:0.356082:0.207946:0.011118:0.005798:0.005217:0.011682:0.003421
. Prognos-:@0.393318:0.221951:0.475145:0.221951:0.475145:0.207946:0.393318:0.207946:0.004738:0.005217:0.010126:0.005073:0.011203:0.011511:0.010434:0.011203:0.006643:0.005679
tic factors  for  response to  cisplatin-based :@0.120589:0.236086:0.479892:0.236086:0.479892:0.222081:0.120589:0.222081:0.005798:0.003421:0.011067:0.007748:0.005371:0.011682:0.011067:0.005798:0.011203:0.005148:0.006636:0.004738:0.002998:0.005371:0.011203:0.005148:0.004738:0.002997:0.005078:0.011118:0.006636:0.011665:0.011203:0.010434:0.006636:0.011118:0.007748:0.005798:0.011203:0.004738:0.002998:0.011067:0.003421:0.006636:0.011665:0.003421:0.011696:0.005798:0.003421:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004738
chemotherapy in advanced cervical car-:@0.120589:0.250221:0.475149:0.250221:0.475149:0.236215:0.120589:0.236215:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006729:0.003421:0.010434:0.006739:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.006739:0.011067:0.011118:0.005148:0.009476:0.003421:0.011067:0.011682:0.003421:0.006753:0.011067:0.011682:0.005148:0.005679
cinoma: a Gynaecologic Oncology Group :@0.120589:0.264355:0.479900:0.264355:0.479900:0.250350:0.120589:0.250350:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004486:0.011682:0.004498:0.014915:0.009168:0.010434:0.011682:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004486:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004490:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738
Study. :@0.559983:0.094716:0.615059:0.094716:0.615059:0.080711:0.559983:0.080711:0.008518:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Gynecologic Oncology. :@0.621080:0.094716:0.832712:0.094716:0.832712:0.080711:0.621080:0.080711:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.010759:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
2010;116: :@0.838733:0.094716:0.919277:0.094716:0.919277:0.080711:0.838733:0.080711:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.004738
44-49.:@0.559983:0.107522:0.608303:0.107522:0.608303:0.093517:0.559983:0.093517:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
17.   Randall  ME,:@0.523636:0.120328:0.662011:0.120328:0.662011:0.106323:0.523636:0.106323:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011682:0.010434:0.011716:0.011682:0.003421:0.003421:0.004738:0.004926:0.015719:0.009168:0.004738
  et  al.:@0.662011:0.120328:0.718077:0.120328:0.718077:0.106323:0.662011:0.106323:0.004738:0.004918:0.011118:0.005798:0.004738:0.004916:0.011682:0.003421:0.004738
  Randomised phase III :@0.718077:0.120328:0.919294:0.120328:0.919294:0.106323:0.718077:0.106323:0.004738:0.004928:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.009664:0.011665:0.010434:0.011682:0.006636:0.011118:0.009664:0.003866:0.003866:0.003866:0.004738
trial of whole-abdominal irradiation:@0.559983:0.133134:0.857941:0.133134:0.857941:0.119128:0.559983:0.119128:0.005798:0.005148:0.003421:0.011682:0.003421:0.007167:0.011203:0.005371:0.007167:0.014214:0.010434:0.011203:0.003421:0.011118:0.005679:0.011682:0.011665:0.011716:0.011203:0.016044:0.003421:0.010434:0.011682:0.003421:0.007167:0.003421:0.005148:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434
 versus:@0.857941:0.133134:0.914522:0.133134:0.914522:0.119128:0.857941:0.119128:0.007167:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 :@0.914522:0.133134:0.919260:0.133134:0.919260:0.119128:0.914522:0.119128:0.004738
doxorubicin and cisplatin chemotherapy in :@0.559983:0.145940:0.919281:0.145940:0.919281:0.131934:0.559983:0.131934:0.011716:0.011203:0.008210:0.011203:0.005148:0.010399:0.011665:0.003421:0.011067:0.003421:0.010434:0.004139:0.011682:0.010434:0.011716:0.004139:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004153:0.011067:0.010434:0.011118:0.016044:0.011203:0.005788:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004139:0.003421:0.010434:0.004738
advanced endometrial carcinoma: a Gy-:@0.559983:0.158745:0.914539:0.158745:0.914539:0.144740:0.559983:0.144740:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.006688:0.011118:0.010434:0.011716:0.011203:0.016044:0.011118:0.005798:0.005148:0.003421:0.011682:0.003421:0.006688:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.006688:0.011682:0.006688:0.014915:0.009168:0.005679
necologic Oncology Group Study. :@0.559983:0.171551:0.862166:0.171551:0.862166:0.157546:0.559983:0.157546:0.010434:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.008843:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.008843:0.014915:0.005080:0.011203:0.010399:0.011665:0.008843:0.008518:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
J Clin :@0.866271:0.171551:0.919277:0.171551:0.919277:0.157546:0.866271:0.157546:0.008244:0.008843:0.013906:0.003421:0.003421:0.010434:0.004738
Oncol:@0.559983:0.184357:0.610971:0.184357:0.610971:0.170352:0.559983:0.170352:0.014864:0.010434:0.011067:0.011203:0.003421
. 2006;24:36-44.:@0.610971:0.184357:0.735098:0.184357:0.735098:0.170352:0.610971:0.170352:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
18.   Fleming  GF,:@0.523636:0.197163:0.659751:0.197163:0.659751:0.183158:0.523636:0.183158:0.009479:0.009479:0.004731:0.004738:0.007916:0.000000:0.008292:0.003592:0.011289:0.016215:0.003592:0.010605:0.011682:0.004738:0.003565:0.015086:0.006378:0.004738
  et  al.:@0.659922:0.197163:0.713968:0.197163:0.713968:0.183158:0.659922:0.183158:0.004738:0.003565:0.011289:0.005969:0.004738:0.003565:0.011853:0.003592:0.004738
  Phase  III  trial  of  doxo-:@0.714140:0.197163:0.914551:0.197163:0.914551:0.183158:0.714140:0.183158:0.004738:0.003565:0.010297:0.010605:0.011853:0.006808:0.011289:0.004738:0.003565:0.004037:0.004037:0.004037:0.004738:0.003565:0.005969:0.005319:0.003592:0.011853:0.003592:0.004738:0.003565:0.011374:0.005542:0.004738:0.003565:0.011888:0.011374:0.008381:0.011374:0.005679
rubicin plus cisplatin with or without pa-:@0.559983:0.209969:0.914556:0.209969:0.914556:0.195963:0.559983:0.195963:0.005319:0.010570:0.011836:0.003592:0.011238:0.003592:0.010605:0.008809:0.011836:0.003592:0.010570:0.006808:0.008809:0.011238:0.003592:0.006808:0.011836:0.003592:0.011853:0.005969:0.003592:0.010605:0.008809:0.014385:0.003592:0.005969:0.010605:0.008809:0.011374:0.005319:0.008809:0.014385:0.003592:0.005969:0.010605:0.011374:0.010570:0.005969:0.008809:0.011836:0.011853:0.005679
clitaxel  plus  filgrastim  in  advanced  en-:@0.559983:0.222775:0.914526:0.222775:0.914526:0.208769:0.559983:0.208769:0.011238:0.003592:0.003592:0.005969:0.011853:0.008381:0.011289:0.003592:0.004738:0.006595:0.011836:0.003592:0.010570:0.006808:0.004738:0.006597:0.004250:0.004250:0.003592:0.011682:0.005319:0.011853:0.006808:0.005969:0.003592:0.016215:0.004738:0.006597:0.003592:0.010605:0.004738:0.006595:0.011853:0.011888:0.009647:0.011853:0.010605:0.011238:0.011289:0.011888:0.004738:0.006595:0.011289:0.010605:0.005679
dometrial carcinoma: a Gynecologic :@0.559983:0.235580:0.919293:0.235580:0.919293:0.221575:0.559983:0.221575:0.011888:0.011374:0.016215:0.011289:0.005969:0.005319:0.003592:0.011853:0.003592:0.017771:0.011238:0.011853:0.005198:0.011238:0.003592:0.010605:0.011374:0.016215:0.011853:0.004909:0.017771:0.011853:0.017771:0.015086:0.009339:0.010605:0.011289:0.011238:0.011374:0.003592:0.011374:0.011682:0.003592:0.011067:0.004738
Oncology Group Study.  :@0.559983:0.249997:0.764934:0.249997:0.764934:0.235992:0.559983:0.235992:0.015035:0.010605:0.011238:0.011374:0.003592:0.011374:0.011682:0.009339:0.003498:0.015086:0.005249:0.011374:0.010570:0.011836:0.003498:0.008689:0.005969:0.010570:0.011888:0.009339:0.004909:0.003498:0.004738
J Clin Oncol:@0.763679:0.249997:0.862628:0.249997:0.862628:0.235992:0.763679:0.235992:0.008415:0.003498:0.014077:0.003592:0.003592:0.010605:0.003498:0.015035:0.010605:0.011238:0.011374:0.003421
. 2004; :@0.862799:0.249997:0.919277:0.249997:0.919277:0.235992:0.862799:0.235992:0.004909:0.003498:0.009647:0.009647:0.009647:0.009647:0.004746:0.004738
22:2159-2166.:@0.559983:0.264414:0.671948:0.264414:0.671948:0.250409:0.559983:0.250409:0.009647:0.009647:0.004909:0.009647:0.009647:0.009647:0.009647:0.005850:0.009647:0.009647:0.009647:0.009647:0.004738